Learning from the Past: A Review of Clinical Trials Targeting Amyloid, Tau and Neuroinflammation in Alzheimer’s Disease
- 25 April 2020
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Alzheimer Research
- Vol. 17 (2), 112-125
- https://doi.org/10.2174/1567205017666200304085513
Abstract
Alzheimer’s disease (AD) is the most common neurodegenerative disease and cause of dementia. Characterized by amyloid plaques and neurofibrillary tangles of hyperphosphorylated Tau, AD pathology has been intensively studied during the last century. After a long series of failed trials of drugs targeting amyloid or Tau deposits, currently hope lies in the positive results of one Phase III trial, highly debated, and on other ongoing trials. In parallel, some approaches target neuroinflammation, another central feature of AD. Therapeutic strategies are initially evaluated on animal models, in which the various drugs have shown effectiveness on the target (decreasing amyloid, Tau and neuroinflammation) and sometimes on cognitive impairment. However, it is important to keep in mind that rodent models have a less complex brain than humans and that the pathology is generally not fully represented. Although they are indispensable tools in the drug discovery process, results obtained from animal models must be viewed with caution. In this review, we focus on the current status of disease modifying therapies targeting amyloid, Tau and neuroinflammation with particular attention on the discrepancy between positive pre-clinical results on animal models and failures in clinical trials.Keywords
Funding Information
- Velux Foundation (1123)
This publication has 103 references indexed in Scilit:
- Metal Ionophore Treatment Restores Dendritic Spine Density and Synaptic Protein Levels in a Mouse Model of Alzheimer's DiseasePLOS ONE, 2011
- Methylene Blue Reduces Aβ Levels and Rescues Early Cognitive Deficit by Increasing Proteasome ActivityBrain Pathology, 2011
- Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapyNature Reviews Neuroscience, 2009
- Pathogenic missense MAPT mutations differentially modulate tau aggregation propensity at nucleation and extension stepsJournal of Neurochemistry, 2008
- Alzheimer disease models and human neuropathology: similarities and differencesActa Neuropathologica, 2007
- Aβ42‐driven cerebral amyloidosis in transgenic mice reveals early and robust pathologyEMBO Reports, 2006
- Alzheimer's diseaseThe Lancet, 2006
- Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset FamiliesScience, 1993
- Neuropathological stageing of Alzheimer-related changesActa Neuropathologica, 1991
- Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's diseaseNature, 1991